Relapsed/Refractory Classical Hodgkin Lymphoma research hub

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

This study is looking at a new medicine for people in the UK with Hodgkin Lymphoma that has come back or hasn't responded to other treatments. It aims to check if the new medicine, AZD7789, is safe, what effects it has, and if it helps in treating the cancer.